Some of the current indications for the use of denosumab include osteoporosis in postmenopausal women with high fracture risk and breast cancer patients on aromatase inhibitors with metastatic disease to the bone. Denosumab has been studied in the breast cancer population with no current correlation to CPPD. The gene discussed is CYP19A1; the disease is metastatic neoplasm.